Physician profile
Lois Windes
NPI 1215939277
$654.29
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.16 · 2020: $199 · 2021: $92.78 · 2022: $252 · 2023: $61.14 · 2024: $36.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $98.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $98.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $104.17 | 2020-2023 | |
| Allergan, INC. | $80.47 | 2020 | |
| Paratek Pharmaceuticals, INC. | $74.17 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.41 | 2020-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $44.64 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $42.88 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.72 | 2020-2023 | Xifaxan |
| Esperion Therapeutics, INC. | $33.28 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $24.25 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.32 | 2022 | |
| Vanda Pharmaceuticals INC. | $21.33 | 2021 | |
| Xeris Pharmaceuticals, INC. | $21.27 | 2022 | |
| Genentech USA, INC. | $16.67 | 2020 | |
| Seqirus USA INC | $15.53 | 2022 | |
| Novo Nordisk INC | $15.48 | 2024 | Wegovy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.02 | 2021 | |
| Inogen, INC. | $14.92 | 2023 | Inogen At Home Stationary Concentrator |
| Novartis Pharmaceuticals Corporation | $14.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lois Windes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.